Literature DB >> 3094569

Valpromide inhibits human epoxide hydrolase.

G M Pacifici, M Franchi, C Bencini, A Rane.   

Abstract

The effect of antipileptic drug valpromide (VPM) on the activity of epoxide hydrolase was studied in human adult and foetal liver, kidneys, lungs, intestine and in placenta. The activity of the epoxide hydrolase was measured with both styrene oxide and benzo(a)pyrene-4,5-oxide as substrates. VPM inhibited the epoxide hydrolase obtained from all organs studied. The degree of inhibition was independent of the substrate used. A lowering of the epoxide hydrolase activity by 50% was observed when the concentration of VPM was similar to that of the substrates. VPM competitively inhibited the activity of adult liver epoxide hydrolase with styrene oxide as substrate.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3094569      PMCID： PMC1401128          DOI： 10.1111/j.1365-2125.1986.tb02886.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  24 in total

1.  Rat and human microsomal epoxide hydratase. Immunological characterization of various forms of the enzyme.

Authors:  F P Guengerich; P Wang; P S Mason; M B Mitchell
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds.

Authors:  J W Daly; D M Jerina; B Witkop
Journal:  Experientia       Date:  1972-10-15

4.  Arene oxides: a new aspect of drug metabolism.

Authors:  D M Jerina; J W Daly
Journal:  Science       Date:  1974-08-16       Impact factor: 47.728

5.  Hepatic microsomal epoxide hydrase: a sensitive radiometric assay for hydration of arene oxides of carcinogenic aromatic hydrocarbons.

Authors:  D M Jerina; P M Dansette
Journal:  Mol Pharmacol       Date:  1977-03       Impact factor: 4.436

6.  Liver microsomal epoxide hydrase: activation, inhibition, and immunological properties of the purified enzyme.

Authors:  W Levin; P E Thomas; D Korzeniowski; H Seifried; D M Jerina; A Y Lu
Journal:  Mol Pharmacol       Date:  1978-11       Impact factor: 4.436

Review 7.  Formation of stable epoxides in the metabolism of tricyclic drugs.

Authors:  A Frigerio; M Cavo-Briones; G Belvedere
Journal:  Drug Metab Rev       Date:  1976       Impact factor: 4.518

8.  Rat and human liver microsomal epoxide hydratase. Purification and evidence for the existence of multiple forms.

Authors:  F P Guengerich; P Wang; M B Mitchell; P S Mason
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

9.  Purification of human liver microsomal epoxide hydrase. Differences in the properties of the human and rat enzymes.

Authors:  A Y Lu; P E Thomas; D Ryan; D M Jerina; W Levin
Journal:  J Biol Chem       Date:  1979-07-10       Impact factor: 5.157

10.  Hydration of arene and alkene oxides by epoxide hydrase in human liver microsomes.

Authors:  J Kapitulnik; W Levin; R Morecki; P M Dansette; D M Jerina; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875
View more
  5 in total

Review 1.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 3.  Clinical pharmacology of valpromide.

Authors:  M Bialer
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

4.  Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.

Authors:  F Pisani; A Fazio; G Oteri; E Spina; E Perucca; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

5.  Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase.

Authors:  G M Pacifici; A Temellini; L Giuliani; A Rane; H Thomas; F Oesch
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.